CDKL3 and prostate cancer: Although a tumor-promoting profile of PIAS1, an inhibitor of STAT1, as well as the tumor-inhibiting feature of STAT1 has been reported in prostate cancer [30], our study illustrated that STAT1 is a co-expression gene and potential downstream target of CDKL3, mediating the promotion of prostate cancer development.